# Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™.

> **NCT02574650** · NA · UNKNOWN · sponsor: **Mitralign, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Symptomatic Functional Tricuspid Regurgitation
- Tricuspid Valve Insufficiency
- Heart Valve Disease

## Interventions

- **DEVICE:** Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)

## Key facts

- **NCT ID:** NCT02574650
- **Lead sponsor:** Mitralign, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2018-05
- **Final completion:** 2019-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574650, "Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02574650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*